Jun 23, 2016 | News
T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be...
Jun 8, 2016 | News
T3D Therapeutics, Inc. has achieved a significant clinical trial milestone in its Phase 2a feasibility study in mild to moderate Alzheimer’s disease patients with T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing,...